Dr. Tinkelenberg is an entrepreneurial life science executive with over 25 years of experience that
spans research, operations, business development, corporate finance, and governance. He is
currently a strategic advisor to and angle investor in emerging biotech companies. He was
President, Chief Operating Officer, and Director of Ceramedix, an MSKCC and MSU spin-out
developing a portfolio of first-in-class antibodies that treat organ failure stemming from
endothelial injury. His team at Ceramedix conducted a successful Type B pre-IND meeting with
FDA, obtained and managed NIAID SBIR awards and a Department of Defense contract, obtained
residency in JLABS New York, managed a team of drug development subject matter expert
consultants, and drove research and development and related intellectual property strategy.
Dr. Tinkelenberg has extensive prior management experience, both on the operating and
investing side, and has both private and public company board experience. Dr. Tinkelenberg was
founding CEO of Enumeral, a spin-out of MIT and Harvard, where he oversaw development of
the antibody pipeline and an NCI-funded single cell immune profiling technology that was applied
to the interrogation of human biopsy samples and cell therapy product candidates. He established
and oversaw research collaborations with Merck, Sanofi, Novartis, J&J, and Celgene, among
others.

Earlier in his career, Dr. Tinkelenberg was a Partner at Ascent Biomedical Ventures where
he led diligence and investment in a number of early-stage biotech and medtech companies,
including assisting portfolio companies with syndication of follow-on financings and business
development with potential acquirers. He has held roles with Torreya and Bionest, life sciences
focused strategic advisory and consulting firms respectively. He worked in the Healthcare Banking
group at Robertson Stephens following his postdoc in lipid biochemistry and cell biology at
Columbia University. Dr. Tinkelenberg earned his Ph.D. in molecular genetics from The
Rockefeller University. Dr. Tinkelenberg is an inventor on multiple patents and an author of peerreviewed publications. He earned his B.A. in Biology (with honors) from Grinnell College. He has
been an invited speaker, guest lecturer, and panelist on a wide range of topics including bioscience
careers, entrepreneurship, and venture investing/capital markets. He currently sits on the Board of
Directors of NewYorkBio, which advocates for the life sciences industry in New York State.